Abstract: A multivalent pneumococcal vaccine consisting of immunogenic amounts of purified pneumococcal capsular polysaccharide (substantially absent "C" polysaccharide) of pneumococcal types (Danish designation) 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F, and from none to one or both of 6A and 25, and combinations thereof and methods of purifying pneumococcal capsular polysaccharide types 3, 5, 9V, 10A, 11A, 15B, 17F, 19A, 22F and 33F.

Abstract: This disclosure describes certain substituted piperazine-1,4-naphthalenediones useful as anti-asthmatic agents.

Abstract: This invention is concerned with novel 4-[(trialkylsilyl)alkylamino]phenyl compounds and their use as antiatherosclerotic agents.

Abstract: This disclosure describes platinum complexes of 3.beta., 4.alpha.-diamino-1.alpha.,2.alpha.-cyclohexanediol which possess the property of inhibiting the growth of tumors in mammals.

Abstract: Platinum complexes of aliphatic tricarboxylic acids useful for inducing regression and/or palliation of cancer diseases in mammals.

Abstract: Antitumor agents LL-D49194.alpha..sub.1, LL-D49194.beta..sub.1, LL-D49194.beta..sub.2, LL-D49194.beta..sub.3, LL-D49194.gamma., LL-D49194.delta., LL-D49194.epsilon., LL-D49194.xi., LL-D49194.eta., LL-D49194.omega., LL-D49194.omega..sub.2 and LL-D49194.omega..sub.3.

Abstract: This invention is concerned with ureas and thioureas which may be represented by the formula: ##STR1## wherein X represents at least one substituent selected from the group consisting of (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkenyl, (C.sub.1 -C.sub.4)alkynyl, phenoxy, mercapto, amino, (C.sub.1 -C.sub.4)alkylamino, di-(C.sub.1 -C.sub.4)alkylamino, halo, trihalomethyl, (C.sub.1 -C.sub.4)alkanoyl), benzoyl, (C.sub.1 -C.sub.4)alkanamido, haloacetamido, nitro, cyano, carboxy, (C.sub.1 -C.sub.4)carboalkoxy, carbamoyl, sulfamyl, methylenedioxy, phenyl, orthophenylene, tolyl, benzyl, halobenzyl, methylbenzyl; Y is selected from the group consisting of oxygen and sulfur; R.sub.1 and R.sub.2 are different and are independently selected from the group consisting of (C.sub.4 -C.sub.12)alkyl, (C.sub.4 -C.sub.12)alkenyl, (C.sub.4 -C.sub.12)alkynyl, (C.sub.4 -C.sub.12)cycloalkylalkyl, (C.sub.7 -C.sub.14)aralkyl, and (C.sub.7 -C.sub.

Abstract: This disclosure describes symmetrical 1,4-bis(substituted-amino)-5,8-dihydroxyanthraquinones useful as chelating agents and for inducing regression and/or palliation of cancer diseases in mammals.

Abstract: A method of treating diabetes mellitus using arylglyoxals which are known compounds.

Abstract: This invention concerns novel N-[(1H-imidazol-1-yl), (1H-1,2,4-triazol-1-yl) and (3-pyridyl)alkyl]benzenesulfonamides which are useful as inhibitors of thromboxane synthetase enzyme and/or as antihypertensive agents.

Abstract: This disclosure describes novel diaryl-alkanamides. These compounds are useful as pharmaceutical agents for ameliorating atherosclerosis by inhibiting the formation and development of atherosclerotic lesions in the arterial wall of mammals.

Abstract: Arylglyoxals which are new compounds, active as hypoglycemic agents.

Abstract: This disclosure describes the catalyzed rearrangement of trans-dispiro (oxirane-2,9-(10'H)-anthracene)-10',2"-oxirane to 10-hydroxymethyl-9-anthraldehyde.

Abstract: Platinum complexes of polyhydroxylated alkylamines and 2-polyhydroxylated alkyl-1,2-diaminoethanes useful for inducing regression and/or palliation of cancer diseases in mammals.

Abstract: Platinum chelates of 2,3-diamino-substituted-4(3H)-pyrimidinones which are useful as antitumor agents.

Abstract: This disclosure describes certain pyrazolo[1,5-a]pyrimidines useful as hypotensive and/or anxiolytic agents, or as agents for the treatment of cognitive and related neural behavioral problems in mammals.

Abstract: N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas which are inhibitors of thromboxane synthetase enzyme.

Abstract: This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

Abstract: This disclosure describes novel pyrazolylpiperazines useful as hypotensive agents in mammals and as intermediates for the preparation of certain pyrazolo[1,5-a]pryrimidines.

Abstract: This disclosure describes a novel process for the preparation of 9,10-anthracenedicarboxaldehyde by the oxidation of 9,10-bis(chloromethyl)anthracene.